Point-of-Care Coagulation Testing Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Point-of-Care Coagulation Testing Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Point of Care Coagulation Testing Devices Market

The Point of Care Coagulation Testing Devices Market size was valued at USD 1.50 billion in 2020, and the market is now projected to grow from USD 1.53 billion in 2021 to USD 2.44 billion by 2028, exhibiting a CAGR of 6.9% during the forecast period of 2024-2032.

The COVID-19 has impacted the Point Of Care Coagulation Testing Devices Market Growth Negatively. During pandemic the market’s revenues were declining for small businesses to key players. With strict lockdown measures many rules were imposed for non-essential surgeries and patient visits, which led to reduction in non-emergency surgical procedures all around the world. As a result the usage of coagulation testing devices has decreased during preoperative or post-operative conditions. Monitoring devices such as Thromboelastography (TEG), are getting attention from healthcare provider as they are using them to identify various conditions such as venous thromboembolism (VTE) or pulmonary

Haemophilia and Von Willebrand Diseases are bleeding disorder which is becoming very common among people, due to which the market seeing growth in demand for POC testing eventually expanding the Point Of Care Coagulation Testing Devices Market Share. In 2019, according to World Federation Of Haemophilia (WFH) there was approx 195,263 haemophilia patients were present globally. The major reason for rising in geriatric patients with bleeding disorders is age-related changes in homeostatic balance. With the conditions’ rise, healthcare sector needs portable and user-friendly testing devices, and the launch of advanced POC diagnostics devices is fulfilling this evolving needs, eventually accelerating market growth.

The high upfront cost and hospital expenses are making people to go for home-based treatment for conditions like haemophilia and VWD. To fulfil the customers’ need, key players are creating user-friendly point-of-care devices for monitoring coagulation disorders at home. These monitoring devices have various helpful features such as portability, easy to use without having the need to any professional guidance. With these features patients can monitor their health from their home and do not have to worry about hospitals visit.

Comprehensive Analysis of Point of Care Coagulation Testing Devices Market

The Point of Care Coagulation Testing Devices Market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the Healthcare benefit management industry. These segmentations are methodically segregated by types of devices and by end users. The types of devices include, Anticoagulation Monitoring Devices, Prothrombin Time/International Normalized Ratio (PT-INR) Testing Devices, Activated Clotting Time (ACT), Activated Partial Thromboplastin Time (aPTT). However, the end users such as Platelet Function Monitoring Devices, Viscoelastic Coagulation Monitoring Devices, Thromboelastography (TEG), Rotational Thromboelastometry (ROTEM).

North America reached to USD 0.62 billion, in 2020, in the POC Coagulation Testing Devices Market. This region is facing huge number of patients with bleeding disorders, advanced device usage, and higher healthcare spending. As people are preferring these advanced devices to be in comfort the North America is keeping its dominance over the POC market globally. According the reports in 2019, the CDC estimated around 33,000 male haemophilia patients in the U.S.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Werfen (Barcelona, Spain), CoaguSense, Inc. (California, U.S.), Helena Laboratories Corporation (Texas, U.S.), Medtronic (Dublin, Ireland), Abbott (Illinois, U.S.), F. Hoffmann-La Roche Ltd (Basel, Switzerland), Siemens Healthcare GmbH (Munich, Germany), Koninklijke Philips N.V. (Amsterdam, Netherlands), HemoSonics, LLC (Virginia, U.S.), Haemonetics Corporation (Boston, U.S.) these market players provide a level-playing competitive landscape.

January 2021: U.S. FDA has given clearance to Abbott for its rapid handheld traumatic brain injury (TBI) blood test. On i-STAT Alinity platform this test will going to be performed, and the results will be out within 15minutes after the plasma is placed on the test cartridge.

Segmentation Table

Attribute Details

Study Period 2017-2028

Base Year 2020

Estimated Year 2021

Forecast Period 2021-2028

Historical Period 2017-2019

Unit Value (USD billion)

Segmentation Device Type, End-User, and Region

By Device Type Anticoagulation Monitoring Devices

- Prothrombin Time/International Normalized Ratio (PT-INR) Testing Devices

- Activated Clotting Time (ACT)

- Activated Partial Thromboplastin Time (aPTT)

Platelet Function Monitoring Devices

Viscoelastic Coagulation Monitoring Devices

- Thromboelastography (TEG)

- Rotational Thromboelastometry (ROTEM)

Others

By End-User Hospitals & Clinics

Homecare

Others

By Geography North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)

Latin America (Brazil, Mexico, Rest of Latin America)

Middle East & Africa (GCC, South Africa, Rest of the Middle East & Africa)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.